Baron Wealth Management LLC Acquires 15 Shares of Eli Lilly and Company $LLY

Baron Wealth Management LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 642 shares of the company’s stock after acquiring an additional 15 shares during the quarter. Baron Wealth Management LLC’s holdings in Eli Lilly and Company were worth $501,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of LLY. PNC Financial Services Group Inc. increased its position in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. GAMMA Investing LLC increased its position in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock worth $12,278,292,000 after acquiring an additional 14,852,076 shares during the period. Nuveen LLC bought a new position in Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Eli Lilly and Company by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company’s stock valued at $5,469,527,000 after buying an additional 969,376 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Finally, HSBC raised shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and raised their target price for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $947.39.

Eli Lilly and Company Stock Up 2.1%

Shares of NYSE LLY opened at $763.59 on Wednesday. The company has a market capitalization of $722.71 billion, a P/E ratio of 49.91, a price-to-earnings-growth ratio of 1.04 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $939.86. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company’s 50 day moving average price is $740.25 and its 200-day moving average price is $774.23.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the company posted $3.92 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.14% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.